Shots: Artios to receive $30M up front & near-term milestones, ~$860M/ target as option fee along with royalties on sales of each commercialized product. Additionally, Artios has opt-in rights for […]readmore
Tags : Response
Shots: The companies reported that most advanced of four COVID-19 vaccine candidates from their BNT162 mRNA-based vaccine program demonstrated the ability to elicit high SARS-CoV-2 neutralizing titers following the second […]readmore
Shots: On Mar 19, 2020, the company initiates the global P-III study in collaboration with BARDA to assess the efficacy of Actemra/RoActemra (tocilizumab, IV) + SOC vs PBO + SOC […]readmore
Shots: The company submitted report for the FDA’s guidance on Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products clarifying the clinical immunogenicity study for the approval of certain proposed […]readmore